156 related articles for article (PubMed ID: 32131714)
1. Effects of ibrutinib on in vitro platelet aggregation in blood samples from healthy donors and donors with platelet dysfunction.
Ninomoto J; Mokatrin A; Kinoshita T; Marimpietri C; Barrett TD; Chang BY; Sukbuntherng J; James DF; Crowther M
Hematology; 2020 Dec; 25(1):112-117. PubMed ID: 32131714
[No Abstract] [Full Text] [Related]
2. Optimizing Platelet GPVI Inhibition versus Haemostatic Impairment by the Btk Inhibitors Ibrutinib, Acalabrutinib, ONO/GS-4059, BGB-3111 and Evobrutinib.
Denzinger V; Busygina K; Jamasbi J; Pekrul I; Spannagl M; Weber C; Lorenz R; Siess W
Thromb Haemost; 2019 Mar; 119(3):397-406. PubMed ID: 30685871
[TBL] [Abstract][Full Text] [Related]
3. Differences and similarities in the effects of ibrutinib and acalabrutinib on platelet functions.
Series J; Garcia C; Levade M; Viaud J; Sié P; Ysebaert L; Payrastre B
Haematologica; 2019 Nov; 104(11):2292-2299. PubMed ID: 30819914
[TBL] [Abstract][Full Text] [Related]
4. Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation.
Kamel S; Horton L; Ysebaert L; Levade M; Burbury K; Tan S; Cole-Sinclair M; Reynolds J; Filshie R; Schischka S; Khot A; Sandhu S; Keating MJ; Nandurkar H; Tam CS
Leukemia; 2015 Apr; 29(4):783-7. PubMed ID: 25138588
[TBL] [Abstract][Full Text] [Related]
5. Oral administration of Bruton's tyrosine kinase inhibitors impairs GPVI-mediated platelet function.
Rigg RA; Aslan JE; Healy LD; Wallisch M; Thierheimer ML; Loren CP; Pang J; Hinds MT; Gruber A; McCarty OJ
Am J Physiol Cell Physiol; 2016 Mar; 310(5):C373-80. PubMed ID: 26659727
[TBL] [Abstract][Full Text] [Related]
6. Effect of Bruton's tyrosine kinase inhibitors on platelet aggregation in patients with acute myocardial infarction.
Bhatti M; Ayton S; Michail O; Gollop ND; Ryding A; Rushworth S; Bowles K; Geisler T; Flather M
Thromb Res; 2019 Jul; 179():64-68. PubMed ID: 31082751
[TBL] [Abstract][Full Text] [Related]
7. Ibrutinib-related bleeding: pathogenesis, clinical implications and management.
Aguilar C
Blood Coagul Fibrinolysis; 2018 Sep; 29(6):481-487. PubMed ID: 29995658
[TBL] [Abstract][Full Text] [Related]
8. Platelet function and bleeding in chronic lymphocytic leukemia and mantle cell lymphoma patients on ibrutinib.
Dmitrieva EA; Nikitin EA; Ignatova AA; Vorobyev VI; Poletaev AV; Seregina EA; Voronin KA; Polokhov DM; Maschan AA; Novichkova GA; Panteleev MA; Ptushkin VV
J Thromb Haemost; 2020 Oct; 18(10):2672-2684. PubMed ID: 32511880
[TBL] [Abstract][Full Text] [Related]
9. Ibrutinib, but not zanubrutinib, induces platelet receptor shedding of GPIb-IX-V complex and integrin αIIbβ3 in mice and humans.
Dobie G; Kuriri FA; Omar MMA; Alanazi F; Gazwani AM; Tang CPS; Sze DM; Handunnetti SM; Tam C; Jackson DE
Blood Adv; 2019 Dec; 3(24):4298-4311. PubMed ID: 31869418
[TBL] [Abstract][Full Text] [Related]
10. The Btk inhibitor AB-95-LH34 potently inhibits atherosclerotic plaque-induced thrombus formation and platelet procoagulant activity.
Smith CW; Harbi MH; Garcia-Quintanilla L; Rookes K; Brown H; Poulter NS; Watson SP; Nicolson PLR; Thomas MR
J Thromb Haemost; 2022 Dec; 20(12):2939-2952. PubMed ID: 36239466
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of Btk by Btk-specific concentrations of ibrutinib and acalabrutinib delays but does not block platelet aggregation mediated by glycoprotein VI.
Nicolson PLR; Hughes CE; Watson S; Nock SH; Hardy AT; Watson CN; Montague SJ; Clifford H; Huissoon AP; Malcor JD; Thomas MR; Pollitt AY; Tomlinson MG; Pratt G; Watson SP
Haematologica; 2018 Dec; 103(12):2097-2108. PubMed ID: 30026342
[TBL] [Abstract][Full Text] [Related]
12. A detailed examination of platelet function inhibition by nitric oxide in platelet-rich plasma and whole blood.
Zimmermann R; Krueger J; Filipović MR; Ivanović-Burmazović I; Calatzis A; Weiss DR; Eckstein R
Clin Lab; 2013; 59(5-6):629-38. PubMed ID: 23865363
[TBL] [Abstract][Full Text] [Related]
13. PO-54 - Clinical and laboratory characterization of platelet dysfunction caused by ibrutinib treatment in patients with chronic lymphocytic leukemia.
Alberelli MA; Innocenti I; Sica S; Laurenti L; De Candia E
Thromb Res; 2016 Apr; 140 Suppl 1():S196. PubMed ID: 27161742
[TBL] [Abstract][Full Text] [Related]
14. Oral Bruton tyrosine kinase inhibitors selectively block atherosclerotic plaque-triggered thrombus formation in humans.
Busygina K; Jamasbi J; Seiler T; Deckmyn H; Weber C; Brandl R; Lorenz R; Siess W
Blood; 2018 Jun; 131(24):2605-2616. PubMed ID: 29559479
[TBL] [Abstract][Full Text] [Related]
15. Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions.
Levade M; David E; Garcia C; Laurent PA; Cadot S; Michallet AS; Bordet JC; Tam C; Sié P; Ysebaert L; Payrastre B
Blood; 2014 Dec; 124(26):3991-5. PubMed ID: 25305202
[TBL] [Abstract][Full Text] [Related]
16. Effects of combination therapy with low-dose aspirin and warfarin on platelet functions after heart valve replacement.
Kobune K; Inoue M; Morikawa M; Tsuboi M; Takanami Y; Iwane Y; Kudo T
Res Commun Chem Pathol Pharmacol; 1991 Nov; 74(2):153-65. PubMed ID: 1811279
[TBL] [Abstract][Full Text] [Related]
17. The effect of Bruton's tyrosine kinase (BTK) inhibitors on collagen-induced platelet aggregation, BTK, and tyrosine kinase expressed in hepatocellular carcinoma (TEC).
Chen J; Kinoshita T; Gururaja T; Sukbuntherng J; James D; Lu D; Whang J; Versele M; Chang BY
Eur J Haematol; 2018 Jul; ():. PubMed ID: 30030853
[TBL] [Abstract][Full Text] [Related]
18. Ibrutinib-associated bleeding: pathogenesis, management and risk reduction strategies.
Shatzel JJ; Olson SR; Tao DL; McCarty OJT; Danilov AV; DeLoughery TG
J Thromb Haemost; 2017 May; 15(5):835-847. PubMed ID: 28182323
[TBL] [Abstract][Full Text] [Related]
19. Activity of Bruton's tyrosine-kinase inhibitor ibrutinib in patients with CD117-positive acute myeloid leukaemia: a mechanistic study using patient-derived blast cells.
Rushworth SA; Pillinger G; Abdul-Aziz A; Piddock R; Shafat MS; Murray MY; Zaitseva L; Lawes MJ; MacEwan DJ; Bowles KM
Lancet Haematol; 2015 May; 2(5):e204-11. PubMed ID: 26688095
[TBL] [Abstract][Full Text] [Related]
20. Ristocetin-induced platelet aggregation for monitoring of bleeding tendency in CLL treated with ibrutinib.
Kazianka L; Drucker C; Skrabs C; Thomas W; Melchardt T; Struve S; Bergmann M; Staber PB; Porpaczy E; Einberger C; Heinz M; Hauswirth A; Raderer M; Pabinger I; Thalhammer R; Egle A; Wendtner CM; Follows G; Hoermann G; Quehenberger P; Jilma B; Jaeger U
Leukemia; 2017 May; 31(5):1117-1122. PubMed ID: 27909342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
